Drug
Mbg453
Mbg453: highest development phase Phase 1/2, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| MBG453 NCT02608268 | Phase 1/2 | Advanced Malignancies |
Latest
No recent events.
Follow Mbg453 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.